Utomilumab

Drug Profile

Utomilumab

Alternative Names: 4-1BB agonist antibody - Pfizer; PF-05082566; PF-2566; PF-5082566

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 24 Feb 2017 Pfizer and Merck completes a phase I trial for Solid tumours (Late-stage disease, Combination therapy) in USA (NCT02179918)
  • 14 Nov 2016 Pfizer establishes CRADA with National Cancer Institute for the development of utomilumab, avelumab and PF 04518600 in Immunotherapy
  • 04 Jun 2016 Preliminary efficacy and adverse events data from the phase Ib KEYNOTE-0036 trial in Solid tumours (Combination therapy, Late-stage disease) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top